A hazard ratio (HR) is a number from a statistical study that compares the rate at which an event, like developing mesothelioma or dying from it, happens in an exposed group versus a comparison group over time. An HR of 1 means no difference; an HR of 2 means the exposed group is developing the disease at roughly twice the rate of the unexposed group at any given moment during follow-up. It is one of the most common ways epidemiologists summarize how strongly an exposure is linked to a disease.
Origin
The hazard ratio comes from survival analysis methods developed in the mid-20th century, most notably the Cox proportional hazards model published by British statistician Sir David Cox in 1972. It quickly became a standard tool in occupational and cancer epidemiology, including studies of asbestos-exposed workers.
Significance in Asbestos Context
Hazard ratios appear throughout the scientific literature your experts will rely on to link asbestos exposure to mesothelioma, lung cancer, asbestosis, and other diseases. A study reporting an HR of 5 for mesothelioma among insulators, for example, tells the court that insulators developed mesothelioma at five times the rate of an unexposed population, powerful evidence of general causation. Defendants often attack hazard ratios by pointing to wide confidence intervals, confounding factors like smoking, or differences between the study population and the patient. Understanding what an HR does and does not show helps you follow expert reports and depositions without being misled by either side's spin on the numbers.
Example Sentence
The plaintiff's epidemiologist testified that a hazard ratio of 4.2 for pleural mesothelioma among shipyard workers, drawn from a large cohort study, supported the conclusion that her late husband's Navy service was a substantial cause of his disease.
Related Terms
Relative Risk, Cohort Study, Confidence Interval, Bradford Hill Criteria, Confounding, Dose-Response Relationship
Notes
- When reading an expert report, look for both the hazard ratio and its 95% confidence interval. A narrow interval that stays well above 1 is stronger evidence than a wide one that barely excludes 1.
- Ask your legal team which specific epidemiological studies and hazard ratios their experts will rely on for your occupation or exposure setting (e.g., shipyard, insulation, automotive, household contact).
- Hazard ratios describe groups, not individuals; your expert must still connect the population-level risk to your particular exposure history, which is where work records, product identifications, and witness statements matter.
- Be aware that defense experts may cite studies with lower hazard ratios or argue that the cited studies do not match your exposure circumstances. Preserving detailed job histories helps your experts respond.
In the research library
289 studies in our medical research library mention Hazard Ratio in the title or abstract. Among the most cited:
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trialG. Zalcman, J. Mazieres, J. Margery, et al, 2016 · Lancet · cited 762 times
- Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility studyT. Treasure, L. Lang-Lazdunski, D. Waller, et al, 2011 · The Lancet. Oncology · cited 527 times
- Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trialM. Maio, A. Scherpereel, L. Calabrò, et al, 2017 · The Lancet. Oncology · cited 339 times
- High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapyS.C. Kao, N. Pavlakis, R. Harvie, et al, 2010 · Clinical Cancer Research · cited 267 times
- A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trialS. Popat, A. Curioni-Fontecedro, U. Dafni, et al, 2020 · Annals of Oncology · cited 229 times
The journals that publish most on it: Journal of Thoracic Oncology (18), Annals of Surgical Oncology (10), Cancers (10).
Category: Epidemiological Methods · All Lexicon terms A–Z
This page is provided for general informational purposes and does not constitute legal advice. Every asbestos case turns on its own facts, exposure history, diagnosis, deadlines, available evidence, and applicable law. Reviewing this page does not create an attorney-client relationship. For advice about your specific situation, call 833-4-ASBESTOS for a free case review.